Skip to main content

Complete CMV diagnostics to improve patient outcomes:

1. Early Detection of CMV Reactivation, Primary Infections
2. Monitor Response to Treatment
3. Confirm Antiviral Resistance
4. Establish Immunity 

Benefits of working with Eurofins Viracor:

  • Industry leading turnaround time for all of our CMV Assays

  • Assay refinement using dual targets, multiple probes and mutation surveillance ensures your patient will be evaluated using the most up-to-date and accurate testing

  • Ability to send all of your CMV testing to one lab:
  • Multiple specimen types accepted for ease of collection

CMV Testing for Transplant & Immunocompromised Patients


  Test Name Test Code Turnaround Time & Test Details  
Viral Load
CMV Real-time Quantitative PCR


  • Same day (within 8-12 hours from receipt of specimen)
  • Most specimen types offer quantitative results
  • Over 19 specimen types
CMV Saliva Real-time PCR


  • Same day (within 8-12 hours from receipt of specimen)
  • Saliva samples are simple, noninvasive, and easy to collect for congenital CMV detection
  • Sample collection within 21 days after baby is born to confirm diagnosis



CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir


  • Within 2-4 days of receipt of specimen (often reported in just 2.5 days)
  • Plasma specimen type
  • DNA viral load must be above 1000 uL/mL to run—one of the lowest minimum viral loads in the industry

CMV Resistance: Maribavir, Ganciclovir, Foscarnet, Cidofovir


CMV Resistance: Letermovir


Immunity CMV inSIGHT™ T Cell Immunity Panel 30360
  • 2-3 days from receipt of specimen
  • Whole Blood in sodium heparin
  • Live Cell tests have special collection and shipping requirements

Innovations in CMV Immunity

CMV inSIGHT™ T Cell Immunity Assay

  • Assess current immune response for viral target

  • Confirm if virus specific CD4 and CD8 T Cells are present

  • Evaluate treatment decisions


Evaluating Cytomegalovirus Cell Mediated Immunity Diagnostic Assays

Explore data on various CMV cell mediated immunity assays and how they can potentially benefit your immunocompromised patients.

Watch how Viracor's CMV T Cell Immunity Panel Helps A Post-Transplant CMV Treatment Plan

Understand how your patient's immune system is responding to CMV medication.


1 Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. Apr 15 2010;89(7):779-95.

2 Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9.

Back to top